BIOASSAY OF GROWTH HORMONE AND PROLACTIN PREPARATIONS BY DETERMINATION OF LONGITUDINAL BONE GROWTH WITH TETRACYCLINE

1974 ◽  
Vol 76 (1) ◽  
pp. 35-52 ◽  
Author(s):  
K.-G. Thorngren ◽  
L. I. Hansson

ABSTRACT The growth stimulating effect of different growth hormone and prolactin preparations on the longitudinal bone growth in thyroxine-treated hypophysectomized rats was determined by the tetracycline method. The effect of the hormone preparations was compared with that of the 1st International Standard for growth hormone. The potency calculation showed that the tested human growth hormone preparations have a higher potency than the bovine, ovine and porcine growth hormone preparations. Also potency differences were found between hormones from the same species but prepared by different methods. The prolactin preparations have a considerably lower growth promoting activity than the growth hormone preparations. The bioassay method used in the present investigation has a favourable mean precision (λ = 0.172) and sensitivity compared with the earlier bioassay methods. The present method increases the possibility of determining the biological effects of various growth promoting substances.

1986 ◽  
Vol 111 (1) ◽  
pp. 3-9
Author(s):  
Karl-Göran Thorngren ◽  
Bengt Hallengren

Abstract. Biological growth activity (bioassayable GH) was determined in blood from healthy individuals and from patients with acromegaly using the rate of longitudinal bone growth in hypophysectomized rats with tetracycline as intravital marker. Also radioimmunoassayable GH and somatomedin A activity were determined. In pooled plasma or serum from normal subjects no bioassayable growth activity was demonstrated. In the clinically active acromegalic patients as a group as well as in one individual patient there was a significant (P <0.05) bioassayable growth activity in serum as compared to serum from normal subjects. The bioassay determination of GH in plasma/serum from normal subjects and acromegalic patients was hampered by the toxicity and the problems connected with the administration of large volumes.


1984 ◽  
Vol 107 (2) ◽  
pp. 192-198 ◽  
Author(s):  
A. Skottner ◽  
A. Forsman ◽  
E. Löfberg ◽  
K.-G. Thorngren

Abstract. In hypophysectomized male rats the biological effects of two batches of methionyl human growth hormone, Somatonorm®, (met-hGH), have been compared to those of human pituitary growth hormone, Crescormon® (hGH). The rats were treated with doses ranging from 10 mIU per day to 145 mIU per day for 10 days. The parameters studied were total weight gain, longitudinal bone growth, measured by the tetracycline method and indirect cartilage growth, measured by uptake of radioactive sulphate. The results obtained demonstrated that Somatonorm® stimulated weight increase in a linear and dose-dependent way, similar to that seen with the native hormone. Longitudinal bone growth, measured by the tetracycline method and the growth of different cartilages, measured as uptake of radioactive sulphate, were also similar between the two hormones.


1974 ◽  
Vol 75 (4) ◽  
pp. 653-668 ◽  
Author(s):  
K.-G. Thorngren ◽  
L. I. Hansson

ABSTRACT The longitudinal bone growth of proximal tibia determined by tetracycline in hypophysectomized rats was used for the bioassay of growth hormone. Female Sprague-Dawley rats were hypophysectomized at 60 days of age and after a post-operative control period of 15 days growth hormone (NIH-GH-B16) was given daily for 5 or 10 days followed by a 10 day period after its withdrawal. A linear log dose-response relation was found for the two administration models with high precision. In the present investigation the longitudinal bone growth was more favourable as a growth parameter for the bioassay of growth hormone than the body weight and the width of the proximal tibial growth plate.


1982 ◽  
Vol 99 (1) ◽  
pp. 24-30 ◽  
Author(s):  
John-Olov Jansson ◽  
Kerstin Albertsson-Wikland ◽  
Staffan Edén ◽  
Karl-Göran Thorngren ◽  
Olle Isaksson

Abstract. The effect of frequency of growth hormone (GH) administration on longitudinal bone growth and body weight was studied in hypophysectomized rats which were given replacement therapy with corticosteroids, thyroxine and GH with start of therapy on the day of surgery. Longitudinal bone growth, as determined by the tetracycline method, was measured during the last 5 days of the 9 day long period with replacement therapy. The daily replacement dose of GH (bGH-17:NIH) was 200 μg and was given on 1, 2, 4 or 8 occasions. Longitudinal bone growth was enhanced in the groups of animals receiving the hormone on two or more occasions per day. The most pronounced response was seen with an administration frequency of four times per day. Changes in body weight during the injection period showed similar changes. The results of the present study show that the administration frequency of growth hormone is important for the growth rate in hypophysectomized rats which have been given replacement therapy. The findings suggest that the secretory pattern of GH is an important factor for optimum growth.


1977 ◽  
Vol 84 (3) ◽  
pp. 497-511 ◽  
Author(s):  
K.-G. Thorngren ◽  
L. I. Hansson

ABSTRACT The effect of the administration frequency of growth hormone on longitudinal bone growth was investigated with tetracycline as intravital marker of the bone growth of the proximal tibia in hypophysectomized rats. The total dose of growth hormone (NIH-GH-B16) and the administration period were the same in all compared experiments. It was possible to achieve an optimum growth response for a certain total dose of growth hormone by increasing the injection frequency. The period of hormone administration was 10 or 5 days followed by a 10 days withdrawal period. When the growth hormone was administered alone or in association with L-thyroxine for 10 days, the optimum injection frequency for growth hormone was found to be 1 inj./day in hypophysectomized rats and 2 inj./day in thyroxine-treated hypophysectomized rats. When the administration period was 5 days for growth hormone given in association with L-thyroxine, the growth stimulation induced by one daily growth hormone injection was the same as that induced by two or four daily injections of the same total dose. An increase in the administration frequency for a total daily dose of thyroxine from 1 to 2 inj./day did not increase the longitudinal bone growth either when thyroxine was given alone or in association with growth hormone.


1982 ◽  
Vol 114 (2) ◽  
pp. 261-265 ◽  
Author(s):  
JOHN-OLOV JANSSON ◽  
KERSTIN ALBERTSSON-WIKLAND ◽  
STAFFAN EDÉN ◽  
KARL-GÖRAN THORNGREN ◽  
OLLE ISAKSSON

Endocrinology ◽  
2007 ◽  
Vol 148 (4) ◽  
pp. 1590-1597 ◽  
Author(s):  
George N. Cox ◽  
Mary S. Rosendahl ◽  
Elizabeth A. Chlipala ◽  
Darin J. Smith ◽  
Sharon J. Carlson ◽  
...  

1977 ◽  
Vol 84 (3) ◽  
pp. 485-496 ◽  
Author(s):  
K.-G. Thorngren ◽  
L. I. Hansson

ABSTRACT The stimulating effect of different pituitary hormones on longitudinal bone growth was determined with tetracycline as intravital marker in hypophysectomized rats. Growth hormone was found to be the most effective growth stimulating pituitary hormone. At considerably higher doses, thyrotrophic hormone (TSH) and prolactin also showed growth stimulating activity. TSH exerts its effect via the production of thyroxine, whereas the growth stimulation by prolactin seems to be a direct effect of this hormone, similar to the effect of growth hormone. The LH, FSH, ACTH, MSH, vasopressin and oxytocin preparations did not stimulate longitudinal bone growth.


1974 ◽  
Vol 75 (4) ◽  
pp. 669-682 ◽  
Author(s):  
K.-G. Thorngren ◽  
L. I. Hansson

ABSTRACT The growth stimulating effect of growth hormone was determined with tetracycline as intravital marker of the longitudinal bone growth of proximal tibia in female Sprague-Dawley rats hypophysectomized at 60 days of age. After a post-operative control period of 15 days growth hormone (NIH-GH-B16) was given daily for 5 or 10 days followed by a 10 day period after its withdrawal. L-thyroxine was given in association with the growth hormone administration to potentiate the growth stimulation. A linear log dose-response relation was found for the two administration models with a high precision. The thyroxine-treatment increased the sensitivity of the bioassay. An administration period of 5 days was found sufficient for the bioassay of growth hormone in thyroxine-treated hypophysectomized rats. Compared with the earlier bioassay methods for growth hormone, the present bioassay is more favourable when all the factors, such as precision, sensitivity, specificity, and administration period are considered.


Sign in / Sign up

Export Citation Format

Share Document